ARTES Biotechnology and Bio Farma announce collaboration in vaccine development

ARTES and Bio Far­ma announced today to join forces for the devel­op­ment and man­u­fac­tur­ing of vac­cine can­di­dates. The agreed col­lab­o­ra­tion involved the strength of both part­ners. ARTES is spe­cial­ized in cell line and process devel­op­ment, VLP based vac­cines as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal­ly rel­e­vant pro­duc­tion process­es where­as Bio Far­ma is involved in the man­u­fac­tur­ing of vac­cines, serum and oth­er bio­log­i­cal prod­ucts for the Indone­sian domes­tic and inter­na­tion­al mar­kets.

Under this com­mit­ment a first agree­ment for VLP based vac­cine tech­nol­o­gy trans­fer was signed on July 1st in Ban­dung, Indone­sia.

We are extreme­ly delight­ed about the mutu­al­ly agreed col­lab­o­ra­tion. Bio Far­ma is a strong and reli­able phar­ma­ceu­ti­cal part­ner and the only vac­cine and anti­s­era pro­duc­er for humans in Indone­sia. We are more than con­fi­dent, that we along with Bio Far­ma will devel­op vac­cines high­ly rel­e­vant for the Indone­sian and neigh­bor­ing mar­kets. We expect that espe­cial­ly devel­op­ments based on our Metavax® tech­nol­o­gy will con­tribute to Bio Farma´s vac­cine port­fo­lio”, Dr. Michael Pio­ntek, founder and man­ag­ing direc­tor of ARTES Biotech­nol­o­gy.

Metavax® is a patent pro­tect­ed VLP tech­nol­o­gy, based on mod­i­fi­ca­tions to duck hepati­tis B virus. The approach elic­its a high­ly potent immune response and there­fore a broad­er pro­tec­tion than the cur­rent­ly avail­able VLP approach­es.
ARTES´Metavax®platform is suit­able for the devel­op­ment and pro­duc­tion of safe and cost-effec­tive vac­cines.

Mean­while, Gov­ern­ment of Indone­sia, rep­re­sent­ed by Min­istry of Health, Min­istry of Edu­ca­tion and Cul­ture and Min­istry of Research and Tech­nol­o­gy, ful­ly sup­ports this part­ner­ship and will assist in aspects of pol­i­cy to accel­er­ate the devel­op­ment of vac­cines in Indone­sia. The com­mit­ment is deliv­ered at the Nation­al Vac­cine Research Forum, on 2–3 July 2013 in Jakar­ta.